Table 1.
Fourteen microarray-based human lung cancer microRNA expression profiling studies (lung cancer tissue versus normal)
| First author (reference) | Year | Lung cancer patients | Differentially expressed miRNAs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
Origin |
Period |
Cancer type |
Clinical Stage |
No. of collected tissue samples (cancer/normal) |
Platform |
Cut-off criteria |
Total |
Up-regulated features |
Down-regulated features |
| Boeri [19] |
2011 |
Italy |
Jun 2000 to Jun 2006 |
Lung cancer |
Satge I to IV (Stage I 60%) |
52 (28/24) |
The miRNA microarray (Ohio State University, version 2.0) |
P < 0.001 |
56 |
6† |
4† |
| Dacic [20] |
2010 |
USA (Pittsburgh) |
NR |
ADC |
NR |
12 (6/6) |
FlexmiR human microRNA pool (Version 8, Exiqon, Vedbaek, Denmark) |
FC > 20 |
7 |
4 |
3 |
| Gao [21] |
2010 |
China (Jiangsu, First Affiliated Hospital of Nanjing Medical University) |
Apr 2008 to Sep 2008 |
NSCLC |
NR |
16 (8/8) |
miRCURY™ LNA microRNA Arrays (version 10.0, Exiqon, Vedbaek, Denmark) |
FC > 2, P < 0.05 |
27 |
9 |
18 |
| |
|
|
Apr 2008 |
SCC [Ref 33] |
NR |
8 (4/4) |
|
FC > 2 |
31 |
7 |
23 |
| Jang [22] |
2012 |
USA (Minnesota) |
Jan 1997 to Sep 2008 |
ADC |
Stage I to IV (Stage I 68.0%) |
206 (103/103) |
Illumina MicroRNA Profiling |
FC > 1.5, P < 0.01, DR < 0.05 |
20 |
10 |
10 |
| Ma [23] |
2011 |
China (Zhejiang) |
NR |
NSCLC (SCC:3; ADC:3) |
Stage I to IV (Stage I 16.7%) |
12 (6/6) |
Illuminia Technologies “humanMI_V2” |
FDR <0.1 |
1 |
1 |
0 |
| Raponi [24] |
2009 |
USA (Michigan) |
Oct 1991 to Jul 2002 |
SCC |
Stage I to IV (Stage I 55%) |
71 (61/10) |
Ambion mirVana Bioarray (version 2.0) |
Signal intensity (log2) >6 in at least one group |
15 |
13 |
2 |
| Seike [25] |
2009 |
USA (Baltimore: 15; Minnesota:7); Japan (Hamamatsu: 6) |
2000 to 2004 |
NSCLC (ADC around 78%) |
Stage I to IV (Stage I 75%) |
56 (28/28) |
The miRNA microarray (Ohio State University, version 3.0) |
P < 0.01, FDR <0.15 |
18 |
5 |
13 |
| Tan [26] |
2011 |
China (Beijing) |
2000 to 2002 |
SCC |
NR |
68 (34/34) |
CapitalBio platform (CapitalBio Corp.) |
Significance analysis of microarray |
22 |
12 |
10 |
| Võsa [27] |
2011 |
Estonia (Tartu) |
2002 to 2008 |
NSCLC (SCC:18; ADC:20) |
Stage I/II (Stage I 92%) |
65 (38/27) |
Illumina MicroRNA Profiling BeadChip |
FC > 2, P < 0.01 |
60 |
31 |
29 |
| Wang [28] |
2011 |
China (Jiangsu, Nanjing Chest Hospital) |
2006 to 2008 |
NSCLC (SCC:7; ADC:16) |
NR |
46 (23/23) |
μParaflo microfluidic chip technology (Atactic Technologies, Houston, TX, USA) |
FC > 5, P < 0.01 |
40 |
27 |
13 |
| Xing [29] |
2010 |
USA (Baltimore) |
Mar 2000 to Jun 2003 |
SCC |
Stage I |
30 (15/15) |
GeneChipR miRNA Array (Affymetrix, Santa Clara, CA, USA) |
FC > 1.5, P < 0.01 |
25 |
7 |
18 |
| Yanaihara [30] |
2006 |
USA (Baltimore) |
1990 to 1999 |
NSCLC (SCC:39; ADC:65,) |
Stage I to IV (Stage I 62.5%) |
208 (104/104) |
The miRNA microarray Chip (TJU version 1.1) |
P < 0.001 |
43 |
15 |
28 |
| |
|
|
|
SCC |
|
78 (39/39) |
|
|
16 |
10 |
6 |
| |
|
|
|
ADC |
|
130 (65/65) |
|
|
17 |
5 |
12 |
| Yang [31] |
2010 |
China (Shaanxi) |
NR |
SCC |
NR |
6 (3/3) |
miRCURY™ LNA array (version 10.0, Exiqon, Vedbaek, Denmark) |
FC > 1.5, P < 0.05 |
9 |
2 |
7 |
| Yu [32] | 2010 | USA (Baltimore) | NR | ADC | Stage I | 40 (20/20) | Taqman human miRNA array A (System Biosciences, Mountain View, CA) | FC > 1.5, P < 0.01 | 20 | 11 | 9 |
Abbreviations: ADC, adenocarcinoma/adenosquamous carcinoma; FC, fold change; FDR, false discovery rate; miRNAs, microRNAs; NR, not reported; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.
† Only the top ten miRNAs of the identified 56 significantly differentially expressed miRNAs were provided.